LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Home・Aandelen Lijst・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

1.23 -5.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.23

Max

1.31

Belangrijke statistieken
By Trading Economics
Inkomsten	-16M -13M
Verkoop	-15M 14M
EPS	-0.04
Winstmarge	-90.037
Werknemers	103
EBITDA	-16M -10M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+205.38% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	11M 505M
Vorige openingsprijs	6.61
Vorige sluitingsprijs	1.23

Nieuwssentiment

By Acuity

56%

44%

310 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

0.6863 / 0.72 Steun & Weerstand

Lexicon Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 dec 2025, 17:39 UTC

Belangrijke Marktbewegers

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15 dec 2025, 23:44 UTC

Marktinformatie

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

15 dec 2025, 23:38 UTC

Marktinformatie

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15 dec 2025, 22:19 UTC

Marktinformatie

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15 dec 2025, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

15 dec 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15 dec 2025, 21:32 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15 dec 2025, 21:28 UTC

Acquisities, Fusies, Overnames

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15 dec 2025, 21:23 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15 dec 2025, 21:22 UTC

Acquisities, Fusies, Overnames

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

ServiceNow Completes Acquisition Of Moveworks >NOW

15 dec 2025, 21:00 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:57 UTC

Acquisities, Fusies, Overnames

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 dec 2025, 20:36 UTC

Marktinformatie

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15 dec 2025, 20:31 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15 dec 2025, 20:27 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15 dec 2025, 20:15 UTC

Marktinformatie

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15 dec 2025, 19:22 UTC

Marktinformatie

Gold and Silver Gain to Start Week -- Market Talk

15 dec 2025, 18:37 UTC

Marktinformatie

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15 dec 2025, 18:29 UTC

Marktinformatie

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15 dec 2025, 17:58 UTC

Marktinformatie

Canada Housing Market In Search Of a Bottom -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15 dec 2025, 17:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

15 dec 2025, 17:36 UTC

Winsten

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15 dec 2025, 17:30 UTC

Acquisities, Fusies, Overnames

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Peer Vergelijking

Prijswijziging

Lexicon Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

205.38% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 3.97 USD 205.38%

Hoogste 6 USD

Laagste 1.9 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Lexicon Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Lexicon Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.6863 / 0.72Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

310 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.